Steve Chmura1, Kathryn A Winter2, Clifford Robinson3, Thomas M Pisansky4, Virginia Borges5, Hania Al-Hallaq1, Martha Matuszak6, Sean S Park4, Sun Yi7, Yasmin Hasan1, Jose Bazan8, Philip Wong9, Harold A Yoon10, Janet Horton11, Gregory Gan12, Michael T Milano13, Elin Ruth Sigurdson14, Jennifer Moughan2, Joseph K Salama11, Julia White8. 1. University of Chicago Comprehensive Cancer Center, Chicago, Illinois. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. 3. Department of Radiation Oncology, Washington University in St Louis, St Louis, Missouri. 4. Department of Medicine-Medical Oncology, Mayo Clinic, Rochester, Minnesota. 5. University of Colorado-Anschutz Medical Center, Aurora. 6. Department of Radiation Oncology, University of Michigan, Ann Arbor. 7. Department of Radiation Oncology, University of Arizona Medical Center - University Campus, Tucson. 8. Ohio State University Comprehensive Cancer Center, Columbus. 9. Centre Hospitalier de L'Universite de Montréal, Hotel Dieu de Montréal, Montréal, Quebec, Canada. 10. Heartland Cancer Research National Cancer Institute Community Oncology Research Program, Decatur, Illinois. 11. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. 12. New Mexico Minority Underserved National Cancer Institute Community Oncology Research Program, Albuquerque. 13. Department of Radiation Oncology, University of Rochester, Rochester, New York. 14. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract
IMPORTANCE: Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases. OBJECTIVE: To establish safety of SBRT dose schedules in patients with 3 to 4 metastases or 2 metastases in close proximity to each other. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 trial opened on August 4, 2014, and closed to accrual on March 20, 2018. Metastases to 7 anatomic locations were included: bone/osseous (BO), spinal/paraspinal (SP), peripheral lung (PL), central lung (CL), abdominal-pelvic (AP), mediastinal/cervical lymph node (MC), and liver (L). Six patients could be enrolled per anatomic site. The setting was a consortium of North American academic and community practice cancer centers participating in NRG Oncology trials. Patients with breast, prostate, or non-small cell lung cancer with 3 to 4 metastases or 2 metastases in close proximity (≤5 cm) amenable to SBRT were eligible for this phase 1 study. Statistical analyses were performed from December 31, 2017, to September 19, 2019. INTERVENTIONS: The starting dose was 50 Gy in 5 fractions (CL, MC), 45 Gy in 3 fractions (PL, AP, L), and 30 Gy in 3 fractions (BO, SP). MAIN OUTCOMES AND MEASURES: The primary end point was dose-limiting toxicity (DLT) defined by the Common Terminology Criteria for Adverse Events, version 4.0, as specific adverse events (AEs) of grades 3 to 5 (definite or probable per the protocol DLT definition) related to SBRT within 180 days of treatment. Dose levels were considered safe if DLTs were observed in no more than 1 of 6 patients per location; otherwise, the dose at that location would be de-escalated. RESULTS: A total of 42 patients enrolled, 39 were eligible, and 35 (mean [SD] age, 63.1 [14.2] years; 20 men [57.1%]; 30 White patients [85.7%]) were evaluable for DLT. Twelve patients (34.3%) had breast cancer, 10 (28.6%) had non-small cell lung cancer, and 13 (37.1%) had prostate cancer; there was a median of 3 metastases treated per patient. Median survival was not reached. No protocol-defined DLTs were observed. When examining all AEs, 8 instances of grade 3 AEs, most likely related to protocol therapy, occurred approximately 125 to 556 days from SBRT initiation in 7 patients. CONCLUSIONS AND RELEVANCE: This phase 1 trial demonstrated the safety of SBRT for patients with 3 to 4 metastases or 2 metastases in close proximity. There were no treatment-related deaths. Late grade 3 AEs demonstrate the need for extended follow-up in long-surviving patients with oligometastatic disease. Treatment with SBRT for multiple metastases has been expanded into multiple ongoing randomized phase 2/3 National Cancer Institute-sponsored trials (NRG-BR002, NRG-LU002). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02206334.
IMPORTANCE: Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases. OBJECTIVE: To establish safety of SBRT dose schedules in patients with 3 to 4 metastases or 2 metastases in close proximity to each other. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 trial opened on August 4, 2014, and closed to accrual on March 20, 2018. Metastases to 7 anatomic locations were included: bone/osseous (BO), spinal/paraspinal (SP), peripheral lung (PL), central lung (CL), abdominal-pelvic (AP), mediastinal/cervical lymph node (MC), and liver (L). Six patients could be enrolled per anatomic site. The setting was a consortium of North American academic and community practice cancer centers participating in NRG Oncology trials. Patients with breast, prostate, or non-small cell lung cancer with 3 to 4 metastases or 2 metastases in close proximity (≤5 cm) amenable to SBRT were eligible for this phase 1 study. Statistical analyses were performed from December 31, 2017, to September 19, 2019. INTERVENTIONS: The starting dose was 50 Gy in 5 fractions (CL, MC), 45 Gy in 3 fractions (PL, AP, L), and 30 Gy in 3 fractions (BO, SP). MAIN OUTCOMES AND MEASURES: The primary end point was dose-limiting toxicity (DLT) defined by the Common Terminology Criteria for Adverse Events, version 4.0, as specific adverse events (AEs) of grades 3 to 5 (definite or probable per the protocol DLT definition) related to SBRT within 180 days of treatment. Dose levels were considered safe if DLTs were observed in no more than 1 of 6 patients per location; otherwise, the dose at that location would be de-escalated. RESULTS: A total of 42 patients enrolled, 39 were eligible, and 35 (mean [SD] age, 63.1 [14.2] years; 20 men [57.1%]; 30 White patients [85.7%]) were evaluable for DLT. Twelve patients (34.3%) had breast cancer, 10 (28.6%) had non-small cell lung cancer, and 13 (37.1%) had prostate cancer; there was a median of 3 metastases treated per patient. Median survival was not reached. No protocol-defined DLTs were observed. When examining all AEs, 8 instances of grade 3 AEs, most likely related to protocol therapy, occurred approximately 125 to 556 days from SBRT initiation in 7 patients. CONCLUSIONS AND RELEVANCE: This phase 1 trial demonstrated the safety of SBRT for patients with 3 to 4 metastases or 2 metastases in close proximity. There were no treatment-related deaths. Late grade 3 AEs demonstrate the need for extended follow-up in long-surviving patients with oligometastatic disease. Treatment with SBRT for multiple metastases has been expanded into multiple ongoing randomized phase 2/3 National Cancer Institute-sponsored trials (NRG-BR002, NRG-LU002). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02206334.
Authors: Rohan R Katipally; Sean P Pitroda; Aditya Juloori; Steven J Chmura; Ralph R Weichselbaum Journal: Nat Rev Clin Oncol Date: 2022-07-12 Impact factor: 65.011
Authors: Tugce Kutuk; Robert Herrera; Teuta Z Mustafayev; Gorkem Gungor; Gamze Ugurluer; Banu Atalar; Rupesh Kotecha; Matthew D Hall; Muni Rubens; Kathryn E Mittauer; Jessika A Contreras; James McCulloch; Noah S Kalman; Diane Alvarez; Tino Romaguera; Alonso N Gutierrez; Jacklyn Garcia; Adeel Kaiser; Minesh P Mehta; Enis Ozyar; Michael D Chuong Journal: Adv Radiat Oncol Date: 2022-04-25
Authors: Anita M Werensteijn-Honingh; Petra S Kroon; Dennis Winkel; J Carlijn van Gaal; Jochem Hes; Louk M W Snoeren; Jaleesa K Timmer; Christiaan C P Mout; Gijsbert H Bol; Alexis N Kotte; Wietse S C Eppinga; Martijn Intven; Bas W Raaymakers; Ina M Jürgenliemk-Schulz Journal: Phys Imaging Radiat Oncol Date: 2022-06-30
Authors: Henan Zhang; Jacob J Orme; Haidong Dong; Sean S Park; Feven Abraha; B J Stish; Val J Lowe; Fabrice Lucien; Erik J Tryggestad; Michael S Bold; Lance C Pagliaro; C Richard Choo; Debra H Brinkmann; Matthew J Iott; Brian J Davis; J Fernando Quevedo; William S Harmsen; Brian A Costello; Geoffrey B Johnson; Mark A Nathan; Kenneth R Olivier; Thomas M Pisansky; Eugene D Kwon Journal: Clin Cancer Res Date: 2021-09-30 Impact factor: 13.801
Authors: Rachel F Shenker; Jeremy G Price; Corbin D Jacobs; Manisha Palta; Brian G Czito; Yvonne M Mowery; John P Kirkpatrick; Matthew J Boyer; Taofik Oyekunle; Donna Niedzwiecki; Haijun Song; Joseph K Salama Journal: Cancers (Basel) Date: 2022-05-13 Impact factor: 6.575